预约演示
更新于：2025-08-20
Bromhexine Hydrochloride
盐酸溴己新
更新于：2025-08-20
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 (1963-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C14H21Br2ClN2 |
InChIKeyUCDKONUHZNTQPY-UHFFFAOYSA-N |
CAS号611-75-6 |
关联
39
项与 盐酸溴己新 相关的临床试验CTR20244253
吸入用盐酸溴己新溶液改善成人下呼吸道感染疾病黏痰症状的有效性和安全性的多中心、随机、双盲、安慰剂平行对照临床研究
CTR20241734
盐酸溴己新片生物等效性试验
CTR20241528
盐酸溴己新片在健康研究参与者中的单剂量、随机、开放、交叉、两周期空腹和餐后人体生物等效性试验
100 项与 盐酸溴己新 相关的临床结果
登录后查看更多信息
100 项与 盐酸溴己新 相关的转化医学
登录后查看更多信息
100 项与 盐酸溴己新 相关的专利（医药）
登录后查看更多信息
776
项与 盐酸溴己新 相关的文献（医药）2025-06-01JOURNAL OF FOOD COMPOSITION AND ANALYSIS
Development and validation of a UHPLC-MS/MS method for the simultaneous determination of coccidiostats, NSAIDs, sedatives, and antiparasitics in hen eggs
作者: Coscolla, Clara ; Igualada, Carmen ; Miralles, Pablo ; Moragues, Francisco
Due to Regulation (EU) 2022/1644, it is required for the first time to monitor veterinary drug residues of coccidiostats and antiparasitics (groups A3d, B2), non-steroidal anti-inflammatory drugs (NSAIDs), sedatives (groups A2d, A3f), and other substances (group B1e) in eggs.This work contains the first method addressing the simultaneous determination of 22 pharmacol. active substances of those families in hen eggs, following the requirements of Regulation (EU) 2021/808, recently amended by Regulation (EU) 2024/2052.Sample preparation was based on a liquid extraction (with acetonitrile and Na2SO4) followed by solid phase extraction, as a cleanup step, and anal. by UHPLC-MS/MS.After method development, the anal. figures of merit were evaluated, observing satisfactory relative matrix effects (≤ 20 %), linearity (R2 ≥ 0.98), accuracy (85-113 %), trueness (-15 to +13 %), repeatability (2.5-18.2 %), reproducibility (3.5-23.1 %), specificity (blank signals <30 % of limit of quantification), and ruggedness (78-130 %).The method limits of quantification values ranged from 0.5 to 30 μg kg-1, with decision limit for confirmation (CCα) values from 0.57 to 335.26 μg kg-1.
2025-04-08ACTA CHROMATOGRAPHICA
Determination of four dry cough medications in fixed dose form by developed stability indicating liquid chromatography-photodiode array detection
作者: Chandrashekar, C. ; Jagadeesh, K. ; Guttula, Rama Swamy ; Suresh Varma Dendukuri, B. N. ; Leela Kumari, B. ; Saroja, J.
Abstract:
This study deals with the development of HPLC assay method for the determination of guaifenesin (GUF), bromhexine (BRH), chlorpheniramine (CHP), and dextromethorphan (DEE) in bulk and Leekuf tablets. Column C18 Aligent eclipse was used to analyse GUF, BRH, CHP and DEE. The H3PO4 (0.01%) and methanol combined in 70:50 (vol/vol) parts was used as mobile phase. The HPLC assay method was validated in accordance with the ICH prerequisite and was capable of providing accurate (99.90% recovery for BRH, 99.40% recovery for CHP, 100.00% recovery for GUF and 99.50% for DEE) and precise (0.160–0.805% RSD range for GUF, BRH, CHP and DEE) quantitative results under slight variations in chromatographic circumstances in the range of quantities 25–150 μg mL−1 (GUF), 2–12 μg mL−1 (BRH), 0.5–3 μg mL−1 (CHP) and 2.5–15 μg mL−1 (DEE). These results concluded that HPLC assay method developed was beneficial for the evaluation of GUF, BRH, CHP and DEE simultaneously in commercial tablet dose. The degradants eluted are well resolved from the GUF, BRH, CHP, and DEE peaks, showing that the process is stability indicating.
2025-02-01SCIENCE OF THE TOTAL ENVIRONMENT
Suspect screening and quantitative analysis of 165 contaminants of emerging concern in water, sediments, and biota using LC-MS/MS: Ecotoxicological and human health risk assessment
Article
作者: Verruck, Silvani ; Lemos Dal Pizzol, Juliana ; Rocha, Gustavo ; Amaral Alexandre, Luan ; Rocha Ribas, Mateus ; Perin, Maurício ; Alves de Oliveira, Luan Valdemiro ; Kasuko Palmeiro, Jussara ; Hoff, Rodrigo ; da Silva, Alice Cristina
This study aimed to implement a targeted multiple reaction monitoring (MRM) screening strategy using liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) for the initial detection of 165 compounds of emerging concern (CECs) in water, sediment, and fish samples. Following the screening, confirmatory and quantitative analyses were conducted using analytical standards for the detected compounds. Qualitative results were confirmed using high-resolution mass spectrometry (HRMS) for those CECs without available standards. Ecotoxicological and human health risk assessments were performed for the quantified CECs. The analysis identified 35 suspect CECs (12 quantified with analytical standards), including parent compounds and metabolites of anti-inflammatories, antibiotics, antidepressants, sedatives, stimulants, and illicit drugs. High concentrations of these CECs were particularly evident near a Wastewater Treatment Plant (WWTP), where notable levels of compounds such as caffeine (4.02-15.03 ng L-1), ciprofloxacin (6.05 ng L-1), clindamycin (6.04-7.01 ng L-1), and diclofenac (1.36-2.20 ng L-1) were detected. Sediment samples exhibited the highest incidence of CECs, with caffeine reaching the highest concentration (55.89 μg kg-1). Ciprofloxacin (2.94 to 4.18 μg kg-1) was the sole CEC detected in biota samples. The ecotoxicological risk assessment indicated that the concentrations of all detected compounds posed significant ecotoxicity risks to the aquatic environment. In particular, caffeine and diclofenac presented considerable acute and chronic toxic risks to aquatic organisms, including algae, crustaceans, and fish. The Hazard Index (HI) values (3.65-7 to 8.06-8) suggest that ingesting ciprofloxacin at the concentrations found in fish does not represent a significant risk to human health. However, due to the reported risks to estuarine biota, it is crucial to continuously monitor the accumulation of these compounds in food widely consumed by the local population to assess potential impacts on human health.
100 项与 盐酸溴己新 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性鼻窦炎 | 临床3期 | 中国 | 2021-07-06 | |
| 慢性支气管疾病 | 临床3期 | 中国 | 2021-07-06 | |
| 慢性鼻窦炎 | 临床3期 | 中国 | 2021-07-06 | |
| 下呼吸道感染 | 临床3期 | 中国 | 2021-07-06 | |
| 气管支气管炎 | 临床3期 | 中国 | 2021-07-06 | |
| 支气管扩张 | 临床3期 | 中国 | 2021-04-07 | |
| 支气管肺炎 | 临床3期 | 中国 | 2021-04-07 | |
| 肥胖 | 临床前 | 伊朗 | 2025-05-26 | |
| 肥胖 | 临床前 | 瑞典 | 2025-05-26 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 50 | (Control Group) | 鹽襯獵艱範憲簾鏇襯築 = 壓淵衊壓網醖膚餘餘遞 繭膚願餘夢餘鬱積鬱醖 (窪鏇壓窪壓餘鹽鏇鏇網, 鹹膚積壓繭鏇繭鬱淵蓋 ~ 鏇艱廠醖鏇鹽膚範獵襯) 更多 | - | 2022-04-13 | ||
(Bromhexine Hydrochloride Group) | 醖構衊簾繭膚繭餘窪顧(顧構觸壓鏇餘範廠齋鑰) = 糧餘廠憲網淵鬱鹽顧獵 積醖鹹壓艱衊繭鹽製廠 (艱齋範構憲襯獵製鏇膚, 顧鹽繭窪廠鏇顧廠構繭 ~ 窪壓鬱憲築製鹽壓襯壓) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用